It is noteworthy that glioma patients with IDH1 or IDH2 mutations tend to have better prognoses than those with the wild-type form of these genes (median survival in GBM-IDH wild-type: 15 months [34]; IDH mutant: 31 months). The gene discussed is IDH1; the disease is central nervous system cancer.